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Type I interferon protects neurons from prions
in in vivo models
Daisuke Ishibashi,1 Takujiro Homma,2 Takehiro Nakagaki,1 Takayuki Fuse,1 Kazunori Sano,3
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Infectious prions comprising abnormal prion protein, which is produced by structural conversion of normal prion protein, are
responsible for transmissible spongiform encephalopathies including Creutzfeldt-Jakob disease in humans. Prions are infectious
agents that do not possess a genome and the pathogenic protein was not thought to evoke any immune response. Although we
previously reported that interferon regulatory factor 3 (IRF3) was likely to be involved in the pathogenesis of prion diseases,
suggesting the protective role of host innate immune responses mediated by IRF3 signalling, this remained to be clarified. Here, we
investigated the reciprocal interactions of type I interferon evoked by IRF3 activation and prion infection and found that infecting
prions cause the suppression of endogenous interferon expression. Conversely, treatment with recombinant interferons in an ex
vivo model was able to inhibit prion infection. In addition, cells and mice deficient in type I interferon receptor (subunit interferon
alpha/beta receptor 1), exhibited higher susceptibility to 22L-prion infection. Moreover, in in vivo and ex vivo prion-infected
models, treatment with RO8191, a selective type I interferon receptor agonist, inhibited prion invasion and prolonged the survival
period of infected mice. Taken together, these data indicated that the interferon signalling interferes with prion propagation and
some interferon-stimulated genes might play protective roles in the brain. These findings may allow for the development of new
strategies to combat fatal diseases.
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Introduction
Human prion diseases, including Creutzfeldt-Jakob disease,
are transmissible neurodegenerative disorders for which no
effective treatment is currently available. Prions are protein-
aceous infectious pathogens distinct from bacteria or
viruses. Accumulation of the structurally abnormal prion
protein (PrPSc) causes pathological changes such as
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neuronal death in the brain, resulting in rapidly progressive
cognitive disorders. PrPSc, which is highly enriched in
b-sheet secondary structures, causes misfolding of normal
cellular PrP (PrPC) (Prusiner, 1998; Weissmann et al.,
2002). In a widely-accepted model of the molecular mech-
anism of prion pathogenesis, following the expression or
introduction of PrPSc, the pathogenic proteins accumulate
in and on neurons; subsequently, various inflammatory re-
sponses occur and induce neuronal death (Tamguney et al.,
2008; Aguzzi et al., 2013). One pathological feature asso-
ciated with prion infection is widespread diffuse gliosis.
However, the host–pathogen interaction in these diseases
remains incompletely understood.
Viral and bacterial pathogens induce various immunolo-
gical responses in the host to eliminate foreign pathogens
from the body. Because the amino acid sequence of PrPSc is
identical to that of PrPC, which is encoded by a host gene,
the host immune system was initially thought not to recog-
nize the prion pathogen (Aguzzi and Polymenidou, 2004).
However, accumulated evidence has shown that prion
infection stimulates pattern recognition receptor (PRR)-
related molecules and related signalling pathways, including
Toll-like receptors (TLRs), interferon regulatory factors
(IRFs), and some cytokines (Prinz et al., 2003; Spinner
et al., 2008; Bradford and Mabbott, 2012; Ishibashi
et al., 2012a; Nuvolone et al., 2015; Kang et al., 2016).
We have also reported that IRF3, which upregulates type I
interferon (I-IFN) in various cell types, including neurons,
plays a role in host defence against prion infection
(Ishibashi et al., 2012a, b), and that persistent prion infec-
tion negatively regulates IRF3 via suppression of the tran-
scription factor Octamer-binding protein-1 (Oct-1)
(Homma et al., 2014a). Prions also exhibit strain diversity
and reciprocal interference between strains, analogous to
viral infections (Dickinson et al., 1972, 1975; Manuelidis,
1998). In addition, the levels of interferon-stimulated genes
with anti-viral functions, including myxovirus resistance
protein, protein kinase R, and 20-50 oligoadenylate synthe-
tase, are significantly elevated at the clinical stage of prion
disease in animal models (Riemer et al., 2000; Baker et al.,
2004; Xiang et al., 2004; Stobart et al., 2007), suggesting
that innate immunity protects the host, at least partially,
against prion infection. In this study, we focused on the
relationship between I-IFN and prion disease and sought
to determine which interferon-stimulated gene induced by




All animal experiments were conducted with approval from
Nagasaki University Institutional Animal Care and Use
Committee (IACUC, approval No. 150371202) and the Safety
Committee for Recombinant DNA Experiments (approval No.
1503311317). The animals were cared for following the
Nagasaki University Guidelines for Animal Experimentation.
Animals
C57BL/6 J mice were purchased from SLC Japan. Tga20 mice
overexpressing normal PrPC were provided by Prof. M.
Horiuchi, Hokkaido University, Japan (Fischer et al., 1996).
Interferon alpha/beta receptor 1 (Ifnar1) knockout mice were
provided by Prof. T. Taniguchi and Dr K. Honda (Current
affiliation: Keio University, Professor), The University of
Tokyo, Japan (Muller et al., 1994). All animals were main-
tained in a pathogen-free environment, at a temperature of
22  2C and humidity of 40 to 70%; food and autoclaved
water were available ad libitum. Mice were periodically in-
spected for hantavirus, lymphocytic choriomeningitis virus,
Sendai virus, parainfluenza virus type 3, pneumonia virus of
mice, rat coronavirus, Mycoplasma pulmonis, and Clostridium
piliforme, and results were consistently negative.
Antibodies and Reagents
Polyinosinic-polycytidylic acid (Poly I:C, Invivogen), Pentosan
polysulfate (PPS, Sigma-Aldrich) and RO4948191, which is an
imidazonaphthyridine with the structural formula 8-(1, 3, 4-oxa-
diazol-2-yl)-2, 4-bis (trifluoromethyl) imidazo [1, 2-a] [1, 8]
naphthyridine (BIONET: RO8191), were purchased from the
indicated vendors. Recombinant mouse IFN- and -b were pur-
chased from Calbiochem (Merck). The mouse monoclonal anti-
body 3S9, recognizing the helix 1 region of PrP, was a kind gift of
Prof. Matsuda, Hiroshima University (Miyamoto et al., 2005).
The anti-PrP polyclonal mouse antiserum (SS), M20 (Santa
Cruz Biotechnology), and the monoclonal (SAF32 and SAF83,
SPI-Bio) antibodies have been described previously (Atarashi
et al., 2006; Ishibashi et al., 2007, 2011; Homma et al.,
2014b). Anti-IFNAR1 (MAR1–5A3, BioLegend), anti-IFN-b
(7F-D3, Santa Cruz Biotechnology), anti-ionized calcium binding
adaptor molecule 1 (Iba-1; Wako Pure Chemical Industries, Ltd),
anti-glial fibrillary acidic protein (GFAP; Dako), anti-murine 2’-5’
oligoadenylate synthetase (OAS1a; C-5, Santa Cruz
Biotechnology), anti-HA (Invitrogen), and b-actin (Sigma) were
mouse, rat, and rabbit monoclonal antibodies, and were pur-
chased from commercial sources. The horseradish peroxidase-con-
jugated anti-goat (Jackson ImmunoResearch Laboratories), anti-
rat (Cell Signaling Technology, Inc.: CST), anti-mouse, and anti-
rabbit (GE healthcare Life Sciences) IgG antibodies were used for
immunoblotting.
Plasmid constructions
The subcloning primers used in this study are summarized in
Supplementary Table 1. The pcDNA3.1 plasmids coding
murine IFN-b (Ifnb) (NCBI accession number:
NM_010510.1) were constructed by inserting the open reading
frame (ORF) region of each gene amplified by nested polymer-
ase chain reaction (PCR) protocol and digested by arbitrary
restriction enzymes. The murine stem cell virus (MSCV) retro-
viral expression vectors, pMSCV (Clontech Laboratories) plas-
mids, coding murine IFNAR1 (NCBI accession number:
M89641.1) and Large T antigen from Simian virus 40
(NCBI accession number: NC_001669) were constructed by
inserting the ORF region of each gene amplified by PCR
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using the primers listed in Supplementary Table 1 and digested
by arbitrary restriction enzymes, respectively. Lentiviral self-
inactivating (SIN) vectors were kindly provided by Dr
Miyoshi of the RIKEN BioResource Center (BRC), Ibaraki,
Japan. CSII-CMV-MCS-IRES2-Venus plasmid coding murine
IFN-b were constructed by inserting the ORF region digested
by NheI and NotI from pcDNA3.1-IFN-b-venus. Experiments
using plasmids inserted with genes coding for the fluorescence
protein ‘Venus’, were performed by Dr Miyawaki of the
RIKEN Brain Science Institute. To manufacture an insertion
region for pUNO-interferon-stimulated response element
(ISRE)-luc, the mammalian expression pUNO vector
(Invivogen), which contains a strong and ubiquitous composite
promoter designated EF1/HTLV, was used. The PCR prod-
ucts were amplified from pTAL-luc (Promega) with specific
primers for a single-round PCR or with two-round PCR
(Supplementary Table 1). The PCR products were inserted
into the pCR-TOPO vector (Invitrogen) and digested by
XhoI and NheI after they were confirmed by sequencing.
Finally, the pUNO-ISRE-luc plasmid was constructed by in-
serting the purified product into the ORF region of the
pUNO vector.
Retroviral vectors using lentiviral
MSCV virus-based system
To prepare the MSCV virus, RetroPack PT67 (Clontech) cells,
containing the Moloney murine leukemia virus (MoMuLV)
gag, pol, and env (10A1 virus-derived) genes, were transfected
with either pMSCV-IFNAR1 or -Large T plasmids using
Lipofectamine 2000 (Invitrogen) after adding 25 mM chloro-
quine for 1 h prior to transfection. The medium was changed
to a fresh growth medium 8 h after transfection. The culture
supernatants were collected 72 h after medium replacement
and filtrated with a 0.45 mm cellulose acetate membrane
Nalgene Syringe Filter (Thermo). For measurement of MSCV
virus titration, NIH3T3 cells were seeded at densities of 105
cells per well in 6-well plates and grown in a humidified incu-
bator at 37C and 5% CO2 overnight to 70–80% confluence.
The cells were treated with serial diluted viral solution (101
to 1012) with 4 mg/ml polybrene and incubated for 24 h. The
remaining colonies in each well were measured by Crystal
violet staining after selection with antibiotics for 1 week. To
prepare the lentivirus, HEK293T cells were co-transfected with
these constructs and lentiviral packaging vectors (SIN vector
plasmid: CSII-CMV-IRES2, packaging plasmid: pCAG-HIVgp
and VSV-G/Rev plasmid: pCMV-VSV-G-RSV-Rev) using
Lipofectamine LTX (Invitrogen). After 16 h, the transfected
cells were added to 10 mM forskolin. After 48 h, the growth
medium, including the lentivirus, was collected and filtrated
with 0.45 mm cellulose acetate membranes, and concentrated
by the Lenti-XTM Concentrator as per the manufacturer’s in-
structions (Clontech). The resultant lentivirus titration was
checked by quantitating the p24 protein using the Lenti-XTM
p24 Rapid Titer Kit (Clontech) in the culture medium.
Cell cultures
Murine neuroblastoma cells (N2a) and fibroblast cells
(NIH3T3) were obtained from the American Type Culture
Collection. To create an in vitro model using cells persistently
infected by prions, N2a-58 cells overexpressing PrPC, which
were established from N2a cells integrating mouse Prnp gene
in N2a cells, were subjected to prion infection with a mouse-
adapted 22 L strain from scrapie as previously described
(Nishida et al., 2000; Ishibashi et al., 2012a). As packaging
cells, HEK293T cells for lentiviral vector system with SIN
virus (provided by Dr Miyoshi in RIKEN BRC) and
NIH3T3-derived RetroPack PT67 cells (Clontech) expressing
10A1 viral envelope protein for MSCV retroviral expressing
system were obtained from commercial sources. All cells were
grown at 37C in 5% CO2 in Dulbecco’s-modified Eagle
medium (DMEM, Wako) containing 4500 mg/l glucose, 10%
heat-inactivated foetal bovine serum (FBS), 100 units/ml peni-
cillin, and 100 mg/ml streptomycin (Nacalai Tesque). Prion-in-
fected and non-infected cells were transfected with Ifnb gene
plasmids using Fugene 6 (Roche) as per the manufacturer’s
protocol, and grown in 6-well plates for 2 days. In the anti-
prion treatment, 20 mg/ml PPS (Caughey and Raymond, 1993),
10 mg/ml anti-PrP antibody (3S9) (Miyamoto et al., 2005) or
0.5 to 500mM RO8191 was added to the prion-infected cells
and incubated for 48 h. In stable line construction, non-tagged
IFN-b-overexpressing cells were established and in vitro 22L
scrapie infection experiments were performed using their
clonal cells. To establish cell lines stably expressing target pro-
teins, pcDNA3.1 plasmids containing target genes were trans-
fected, using Fugene 6 (Roche), into N2a-58 cells, the cells
were then selected by 350 to 500mg/ml HygroGoldTM
(Invivogen) treatment, and drug-resistant colonies were
isolated.
Mouse embryonic fibroblast isolation,
immortalization and establishment of
a stable line
To prepare primary mouse embryonic fibroblasts (MEFs),
mouse embryos from the C57BL/6 and Ifnar1/ pregnant
female mice were isolated and dissected out of the uterine
horns at Days 13 to 15. After rinsing them in 70% ethanol,
each embryo was separated from its placenta, and the brain
and internal organs were removed and placed in a petri dish
containing phosphate-buffered saline (PBS). Sequentially, the
tissues were chopped using razor blades and were suspended
and subdivided by trypsin-EDTA. All of these procedures were
performed using aseptic technique in a biological safety cab-
inet. After centrifugation, these collected cells were resus-
pended and seeded with fresh DMEM, containing 10% FBS,
as described above, in culture dishes. The medium was chan-
ged on the following day and the adhered fibroblast cells were
cultured and passaged until adequate cell volume was
achieved. To establish the immortalizing MEFs, the amplified
fibroblasts from Ifnar1/ mice were subcloned and passaged
by serial replacing with 50 to 100 mg/ml HygroGoldTM selec-
tions of the cells, following infection of MSCV-Large T vector
at a rate to 1012 colony forming units (cfu) per 100 mm culture
dish. The Ifnar1 gene-introduced Ifnar1/ MEFs were estab-
lished by subcloning and passaging with 2.5mg/ml puromycin.
Selection of the cells occurred following infection with the
MSCV-IFNAR1 vector with final concentration of 4 mg/ml
polybrene at a rate to 1012 cfu per 100 mm culture dish.
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Luciferase assay
Ifnar1/ and Ifnar1 gene-transduced Ifnar1/ (Ifnar1-
Ifnar1/) MEF cells were transiently co-transfected with the
plasmids pUNO-ISRE-luc and pRL-null as internal standard
plasmids, using LipofectamineTM LTX, and cultured for 24 h.
The treated cells were continuously transfected with 30 mg/ml
Poly I:C using LipofectamineTM LTX. After 20 h, the cells were
lysed using Passive Lysis Buffer (Promega) and the luciferase
activity was detected by the Dual Reporter Assay System
(Promega) and quantified using the Mithras LB940 lumin-
ometer instrument (Berthold Technologies). Data of luciferase
activity were normalized by value of the co-expressed Renilla
activity as previously described (Homma et al., 2014a).
Prion infection in ex vivo and in vivo
In ex vivo prion infection in cell culture, the cells were infected
with 22 L scrapie strain-infected brain homogenate prepared
from mice terminally sick with the 22 L strain (final concen-
tration 2  103% brain homogenate for neuronal cells;
2  103, 2  102% for NIH3T3 cells; 6  103, 3  102,
1.5  101% brain homogenate for MEF cells) in a 6-well
culture plate for 48 h, and subsequently grown and scaled up
to a 75 cm2 flask. Once confluent, the subcultures were diluted
5- or 10-fold in fibroblast or neuronal cells. In experiments of
the inhibitory effect against prion infection at early phase, I-
IFNs and RO8191 (0.5–500 mM) were treated in the cells and
incubated for 24 h before prion infection simultaneously with
recombinant mouse I-IFNs, and cultured until the fifth passage
(#1 to #5) after scale-up. Poly I:C (0.2 to 2mg/well) stimuli
were transfected by LipofectamineTM LTX and incubated for
8 h before prion infection. In in vivo prion infection, 4-week-
old male mice (wild-type and Ifnar1/ mice of the same
C57BL/6-derived genetic background) were inoculated via the
intracerebral (i.c.) and intraperitoneal (i.p.) route with 22 L-
brain homogenate (i.c.: 20 ml of a 101 and 102 dilution of
brain homogenate; i.p.: 100ml of a 102 and 103 dilution
of brain homogenate). Mice were monitored every other day
until the terminal stage of disease. Clinical onset in prion dis-
ease has been defined as the presence of two or more of the
following signs: greasy and/or yellowish hair, hunchback,
weight loss, yellow pubic hair, ataxic gait, and non-parallel
hind limbs. The prion-infected mice were sacrificed at preclin-
ical onset [100 days post-inoculation (dpi)] and terminal stage,
and the brains and spleens were removed. The right hemi-
sphere of the brains and a part of the spleens were immediately
frozen and homogenized at 20% and 10% (weight/volume) in
phosphate buffered saline, for immunoblotting analysis, and
total proteins were extracted by mixing the same amount of
2 Lysis Buffer as described below. Remaining tissues were
fixed in 4% paraformaldehyde and pathological analysis was
performed. As a negative control (mock), age- and strain-
matched mice were inoculated intracerebrally or intraperitone-
ally with normal mouse brain homogenate. In a bioassay with
RO8191, the drug was dissolved in PBS including 20%
Kolliphor HS 15 (BASF), which is one of the solvents used
for pharmaceutical applications. Four-week-old ddY male
mice purchased from SLC (Hamamatsu) were intracerebrally
inoculated with 20 ml of a 101 dilution of brain homogenate
containing strain 22 L. Sequentially, the mice were intraperito-
neally administered 2.0 mg drug/kg/day every other day. As a
control, age- and strain-matched mice were intraperitoneally
inoculated with the solvents without the drug. Vehicle and
RO8191-treated mice were weighed three times a week from
the moment before onset to the terminal stage of the disease.
In vivo administration of lentiviral
vector
As lentiviral vectors were intracerebrally or stereotaxically ad-
ministered on the ipsilateral side at 3 weeks after the intracer-
ebral injection of 1% 22 L prion brain homogenate injection in
Tga20 mice. The volume of the lentivirus via intracerebral in-
jection was 20 ml (viral titer: 1.5  108 IFU/ml). The volume of
the lentivirus via stereotaxic microinjection was 4ml (viral titer:
1.5  108 IFU/ml). The flow rate was 1ml/min, using auto-
microinjector-equipped Hamilton syringe 700 series
(Narishige) (10 ml), and mounting a 30 gauge needle on the
left hemisphere brain (thalamus coordinates: + 2 mm anterior
to bregma, + 1 mm lateral to the midline and + 4 mm ventral
form the skull surface). Lentivirus coding the Venus gene
vector (LV-venus) was used as a control. To confirm gene ex-
pression by the lentiviral vector, the fluorescent Venus protein
was visualized in mice brain tissues 3 weeks after viral inocu-
lation using the confocal laser-scanning microscope LSM 700
(Carl Zeiss). Nuclei were stained with VECTASHIELD mount-
ing medium containing DAPI (Vector Laboratories).
Immunoblotting
Immunoblotting was performed as previously described
(Homma et al., 2015; Ishibashi et al., 2015). The culture
cells and animal tissues treated with various experimental con-
ditions were lysed in 1  lysis buffer [50 mM Tris-HCl (pH
7.5) containing 150 mM NaCl, 0.5% TritonTM X-100, 0.5%
sodium deoxycholate, 2 mM EDTA, and protease inhibitors
(Nacalai Tesque)], for 30 min at 4C. The lysates were then
treated by sodium dodecyl sulphate (SDS) sample buffer and
were separated with 15% SDS-polyacrylamide gel electrophor-
esis, and blotted to a polyvinylidene difluoride membrane.
Bands were detected by appropriate primary antibodies and
horseradish peroxidase-labelled secondary antibodies, and
visualized using the Chemi-Lumi One L (Nacalai Tesque),
ECL prime Western Blotting Detection Kit (GE Healthcare
Life Sciences), or ClarityTM Western ECL Substrate (Bio-
Rad) to get appropriate results by sufficient enzymatic reac-
tion. Band intensities were quantified using ImageJ software
(NIH). For PrPSc detection, lysates were digested with 20 mg/
ml of proteinase K (Nacalai Tesque) at 37C for 30 min.
Immunofluorescence analysis
In a fluorescence-activated cell sorter analysis, immortalized
cells established from IFNAR1-deficient mouse embryonic
fibroblasts (Ifnar1/ MEF) and the Ifnar1/ cells reintro-
duced with the MSCV retrovirus coded mouse Ifnar1 gene
and overexpressing exogenous IFNAR1 (IFNAR1 Ifnar1/)
were harvested in PBS containing 20 mM EDTA. Cells were
suspended, fixed, and permeabilized with BD Cytofix/
CytopermTM Fixation/Permeabilization Solution Kit (BD
Biosciences), and reacted with anti-SAF32 and MAR1–5A3
(1:100) as primary antibodies, and Alexa Fluor 488 goat
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anti-rabbit and anti-mouse IgG (Molecular Probes, 1:100). The
cells were analysed using a flow cytometer (BD
FACSCaliburTM, BD Biosciences).
Histology
After the mice were sacrificed at the time point, the brain and
spleen tissues were fixed in 10% formalin and sectioned into
3 mm slices that were then embedded in paraffin. To evaluate
spongiform change, the sections were analysed by haematoxy-
lin and eosin staining as previously described (Ishibashi et al.,
2012a; Nakagaki et al., 2013). As per the immunohistochem-
istry protocol, after deparaffinization and rehydration as prep-
aration for pre-staining, the sections were boiled with Target
Retrieval Solution (Dako, S2369), and treated with 0.3%
hydrogen peroxidase in methanol to inactivate endogenous
peroxidase, and sequentially incubated with 1% bovine
serum albumin in Tris-buffered saline-Tween-20 (TBST) at
room temperature for 1 h. The sections were reacted with pri-
mary antibodies and envision polymer horseradish peroxidase-
conjugated anti-rabbit and anti-mouse immunoglobulin G anti-
bodies (Dako, K4002 and K4000) for 1 h at 37C, respect-
ively, and visualized using 3,30-diaminobenzidine. To detect
gliosis, Iba-1 (WAKO, 019–19741) for microglia and GFAP
(DAKO, Z033429) for astrocytes, were applied to the sections
as primary antibodies. For PrPSc staining, autoclaving was per-
formed using the hydrochloric acid protocol described previ-
ously (Nakagaki et al., 2013). In this pathological analysis,
brain tissues from the regions of the cortex, hippocampus,
thalamus, cerebellum, and Pons were evaluated. For semi-
quantification in histopathological analysis, the pathological
degree of each region in the tissues was scored on a 0 to 5
scale (i.e. non-detectable, a few, mild, moderate, severe, and
status spongiosis) as described previously (Ishibashi et al.,
2012a).
Quantitative PCR
After prion infection, total RNA was harvested from the cells
and brain tissues using a GenEluteTM Mammalian Total RNA
Miniprep kit (Sigma), according to the manufacturer’s proto-
col. RNA was reverse-transcribed with SuperScript VILO
(Invitrogen), and the resulting cDNA was used in a quantita-
tive PCR through reaction with LightCycler 480 SYBR Green
I Master (Roche Applied Science) and the original primers
listed below, and measured by a Light Cycler 480 instrument
(Roche Applied Science). Murine Irf3 (NCBI accession
number: NM_016849) cDNA was amplified using 50-ACT
GAA AAC CGT GGA CTT GC-30 as the sense primer and
50-AGT CCA TGT CCT CCA CCA AG-30 as the antisense
primer; murine Irf7 (NCBI accession number: NM_016850)
cDNA, using 50- GGT ATG CCG CCA AAT CTA AA-30
and 50-GCT GAG GTC CAA AAT TTC CA-30; murine Tlr3
(NCBI accession number: NM_126166) cDNA, using 50-AGC
TTT GCT GGG AAC TTT CA-30 and 50-GAA AGA TCG
AGC TGG GTG AG-30; murine Tlr4 (NCBI accession
number: NM_021297) cDNA, using 50-CAG CAA AGT
CCC TGA TGA CA -30 and 50-AGA GGT GGT GTA AGC
CAT GC-30; murine Tlr7 (NCBI accession number:
NM_001290755) cDNA, using 50-GGT ATG CCG CCA
AAT CTA AA-30 and 50-GCT GAG GTC CAA AAT TTC
CA-30; murine retinoic acid-inducible gene 1 (Ddx58/RIGI,
NCBI accession number: NM_172689) cDNA, using 50-AAG
GCT GAT GAG GAT GAT GG-30 and 50-TGG TTT CAA
TGG GCT GTG TA-30; murine melanoma differentiation-asso-
ciated gene 5 (Ifih1/MDA5, NCBI accession number: NM_
027835) cDNA, using 50-GCT GCT AAA GAC GGA AAT
CG-30 and 50-TCT TGT CGC TGT CAT TGA GG-30;
murine Ifnb (NCBI accession number: NM_010510.1)
cDNA, using 50-CCC TAT GGA GAT GAC GGA GA-30
and 50-CTG TCT GCT GGT GGA GTT CA-30, respectively.
As an internal standard, mouse b-actin/Actb (NCBI accession
number: NM_007393) cDNA sense primer, 50-AAA TCG
TGC GTG ACA TCA AA-30 and antisense primer, 50-AAG
GAA GGC TGG AAA AGA GC-30, were used (Homma
et al., 2015). The primers of Irf3, Irf7, Tlr3, Tlr7, and Ifih1/
MDA5 were designed to amplify the ORF region, and those of
Tlr4, Ddx58/RIGI, Ifnb, and Actb were designed to amplify
the ORF region across the intron. The results were normalized
for the Actb mRNA level.
Measurement of blood–brain barrier
permeability
To investigate the permeability of RO8191, the BBB KitTM
was used as an in vitro blood–brain barrier screening model
(RBT-24 H, PharmaCo-Cell Co), consisting of co-cultures of
endothelial cells, pericytes and astrocytes, according to the
manufacturer’s protocol (Pervin et al., 2017). In brief, 10 mM
of RO8191 was added to the luminal side as the blood-side in
the BBB KitTM using clear transwell inserts in 12-well plates.
After incubation for 1 h, 200ml of the luminal side medium
and 900ml of the abluminal side as the brain-side medium
were harvested from the culture plate. The concentration of
RO8191 (MW: 373.21) in each sample, including the rest of
the administered original sample, were measured using lipid
chromatography with tandem mass spectrometry (LC-MS/
MS). To quantify blood–brain barrier permeability, the appar-
ent permeability coefficient (Papp) (106 cm/s) was calcu-
lated as described previously (Tominaga et al., 2015).
Measurement of RO8191 from animal
tissues using LC-MS/MS
RO8191-treated and -untreated mice brains and spleens at
100 dpi and terminal phase were homogenated with PBS.
Then 20% homogenate samples were mixed with 99% metha-
nol in a 4-fold volume and were incubated at 80C for 1 h.
The standard samples were prepared from serial dilutions (0.1,
1, 10, 100 and 1000 nM) of compounds mixed with 20%
normal brain homogenate. After centrifugation at 20 000g
for 15 min, supernatants from the sample tissues and standards
were collected, and then subjected to LC-MS/MS. LC-MS/MS
was performed by an acquity UPLC-I class system coupled
with a XevoTM TQ-S triple quadrupole-mass spectrometer
(Waters). Under UPLC conditions, 5ml of sample volume
was delivered to the ACQUITY UPLC BEH C18 column
(1.7 mm, 1.0  100 mm, Waters) for reversed-phase chroma-
tography, with the mobile phase consisting of solvent A
(5 mM ammonium formate in methanol) and solvent B
(ultra-pure water) at a flow rate of 0.35 ml/min at 40C. In
the gradient elution, solvent A was used in the order corres-
ponding to ratios of 10%, 10%, 95% and 10% at each time
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point (0, 1.5, 2.0 and 4.5 min, respectively). To detect the
separated compound, the tandem mass spectrometer was set
in ESI positive ionization mode and in multiple reaction-moni-
toring (MRM) mode. Collision energy and cone voltage were
3000 V and 50 V, respectively. Cone and desolvation gas flow
rates, and the desolvation temperature were set to 150 and
650 l/h, and 350C, respectively. The system was tuned to
monitoring the scan type of MRM with three channels set to
373.98 to 265.00, 373.98 to 331.98 and 373.98 to 347.06 m/z
transition (monitor range, precursor ion to product ion). From
the MRM data, the concentration of RO8191 was acquired by
analysis through MassLynx software (Waters).
Statistical analysis
Statistical analysis of all data was performed using Statcel 2 of
the Excel and GraphPad Prism software. Student’s t-test and
Mann-Whitney U-test were used in the comparisons of two
groups, and the one-way ANOVA followed by the Tukey-
Kramer and Dunnett’s tests in multiple comparisons. The
log-rank test was used to analyse the mortality of prion-in-
fected mice. Results in the graph and table represent the
mean  standard error of the mean (SEM) or standard devi-
ation (SD) of at least three independent experiments.
Data availability
The authors confirm that the data supporting the findings of
this study are available within the article and its
Supplementary material.
Results
Type I IFN is protective against prion
infection in pathological models
In 22 L-scrapie prion-infected cell cultures, an ex vivo model
of prion disease, the TLRs and I-IFN related genes were
significantly downregulated in association with the establish-
ment of infection. Data are represented for PrPSc expression
with primary [younger than postnatal Day (P)5] or consti-
tutive (4P20) infections in Neuro2-a cells overexpressing
mouse PrPC (N2a-58) and immortalized mouse fibroblast
cells (NIH3T3) (Fig. 1A–C and Supplementary Fig. 1A–C).
The reduction in expression of these genes significantly re-
covered when PrPSc levels were decreased by treatment with
PPS (Caughey and Raymond, 1993) or anti-PrP monoclonal
antibody (3S9) (Miyamoto et al., 2005) (see ‘Materials and
methods’ section) (Fig. 1D and Supplementary Fig. 1D), sug-
gesting that prion infection might suppress several innate
immune-related genes in cultured cells.
I-IFN, which defends the host against infectious agents, is
produced not only by immune cells but also by other cell
types including fibroblasts and neurons (Delhaye et al.,
2006). Hence, we investigated the potential anti-prion
effect of recombinant I-IFNs (IFN- and -b) in cell culture
models. In the primary prion-challenge test IFN-b treatment
significantly suppressed PrPSc levels in persistently 22 L-
prion-infected cells, and pretreated cells became resistant to
22 L-prion primary infection in a dose-dependent manner;
the effect of IFN- at similar doses was weaker (Fig. 2A
and B). Similar resistance to prion was also observed in
IFN-b-overexpressing stable cell lines (58-IFN-b) (Fig. 2C
and Supplementary Fig. 2A). Transient IFN-b expression
did not reduce endogenous PrPSc levels in persistently 22 L
prion-infected cells (Supplementary Fig. 2C). Pre-transfection
of cells with Poly I:C, which activates the innate immune
system via I-IFN induction, prevented the establishment of
prion infection in a dose-dependent manner (Fig. 2D). To
evaluate efficacy of IFN-b against prion propagation in
prion infectious animal model, we performed bioassay
using 22 L-prion-infected Tga20 mice with lentivirus
coding Ifnb gene (LV-IFN). Lentiviral vectors were adminis-
tered at 3 weeks after prion infection. LV-IFN localized in
thalamus at 20 days after stereotaxic injection into Tga20
mice brain (Fig. 2E). When lentivirus carrying the mouse
Ifnb gene (LV-IFN) was injected intracerebrally, PrPSc
levels were significantly reduced at the terminal stage in
the brain of Tga20 mice after prion inoculation (Fig. 2F).
In pathological analysis, vacuolation and PrPSc deposits
decreased significantly in the brains of LV-IFN–treated
mice (Supplementary Fig. 2B). The endogenous PrPC level
did not change in response to IFN-b overexpression in
N2a-58 cells (Supplementary Fig. 2D), indicating that IFN-
b might prevent new PrPSc production at the early phase of
primary prion infection without affecting PrPC expression.
Prion infection is accelerated in
IFNAR1-deficient cells and mice
To confirm that the suppression of prion infection by IFNs
was associated with IFN signalling, we generated immortalized
MEF cells from wild-type and IFNAR1-deficient (Ifnar1/)
mice and performed prion infection ex vivo. Susceptibility to
22 L prion infection was remarkably higher in immortalized
MEF cells from Ifnar1/ mice than in MEF cells from wild-
type mice. Prions were dose-dependently propagated in both
MEF cells. IFNAR1/ MEFs showed significantly higher sen-
sitivity to prion infection with 1.5  101 % 22 L-brain hom-
ogenate than MEFs from wild-type (Fig. 3A). Next, we
generated Ifnar1-transduced Ifnar1/ MEF cells, which
were rescued by delivering the Ifnar1 gene to Ifnar1/
MEFs with an MSCV retroviral vector, and investigated the
efficiency of prion infection in an ex vivo model. The PrPC
level was similar between Ifnar1/ MEFs and Ifnar1/
MEFs rescued by delivering the Ifnar1 gene with an MSCV
retroviral vector, but the latter cells were significantly and con-
tinuously less susceptible to 22 L prion infection (Fig. 3B,
Supplementary Fig. 3A and B). To confirm whether the trans-
duction restored IFN signalling, we performed ISRE-promoter
activity analysis using the dual luciferase assay. The results
indicated that the promoter activity in Ifnar1-transduced
Ifnar1/ MEFs after poly I:C stimulation was significantly
increased (3-fold) compared with non-stimulated cells,
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indicating that the transduced cells recovered cell signalling
function via IFNAR1 whereas Ifnar1/ MEFs did not possess
this signalling pathway (Supplementary Fig. 3C). To elucidate
the relationship between I-IFN dependent signalling pathways
and prion infection in vivo, we inoculated 22 L prion into
wild-type and Ifnar1/ mice and monitored prion pathogen-
esis. When mice were challenged intracerebrally with a 101
dilution of 22 L prion brain homogenate, the survival periods
of Ifnar1/ mice were significantly shorter (145  5 days,
n = 15; P = 0.0006, Log-rank test) than those of the wild-
type mice (153  8 days, n = 17) (Fig. 4A and Table 1).
Furthermore, all groups of IFNAR1/ mice inoculated with
102 dilution i.c., or 102 and 103 dilution i.p., also ex-
hibited significantly shortened survival (Table 1). To confirm
pathogenesis in IFNAR1/ mice after prion inoculation, we
performed immunoblotting to examine the PrPSc levels in the
brain and spleen at 100 dpi and at the terminal stage. The
PrPSc levels in the brain and spleen of Ifnar1/ mice were
similar into those of wild-type mice (Fig. 4B and
Supplementary Fig. 3D). However, vacuolation and gliosis
with microglia (marker: IBA1) and astrocytes (marker:
GFAP) were significantly more severe than in wild-type
mice. In addition, accumulation of PrPSc in some regions at
100 dpi was considerably more severe in Ifnar1/ mice (Fig.
4C, D and Supplementary Fig. 3E). Taken together, these
findings indicate that the I-IFN signalling pathway via I-IFN
receptor, including IFNAR1, protects to some degree against
prion infection.
Figure 1 Innate immune-related genes levels are suppressed by prion infection in the cells. (A) Ifnb gene expression in persistently
prion-infected N2a-22 L and non-infected N2a-58 cells. Immunoblot shows PrPSc levels in those cells. (B and C) Irf3 and Ifnb levels in N2a-58 (B)
and NIH3T3 (C) cells after ex vivo prion infection with 2  103 or 2  102 % 22 L-brain homogenate (BH). Pre-infection of N2a-58 cells and
normal brain homogenate treatment in 3T3 cells, white; 22 L-prion infection, black. Immunoblot shows PrPSc levels in those cells after prion
infection. (D) Irf3 and Ifnb levels in N2a-22 L cells for 48 h after PPS and 3S9 treatments. N2a-58 (white); -22 L (black). Immunoblot shows PrPSc
levels in the cells 24 and 48 h after PPS and 3S9 treatment. Statistical significance was determined using unpaired Student’s t-test (A–C) and one-
way ANOVA, followed by Tukey-Kramer test in multiple comparisons (D). *P5 0.05, **P5 0.01, ***P5 0.001. Data are presented as
mean  SEM. Quantitative RT-PCR and western blot results represent at least three independent experiments.
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I-IFN agonist suppresses prion
formation in pathological models
An imidazonaphthyridine with the structural formula 8-(1,
3, 4-oxadiazol-2-yl)-2, 4-bis (trifluoromethyl) imidazo [1, 2-
a] [1, 8] naphthyridine (RO4948191, referred to as
RO8191) is able to block hepatitis C virus infection to
several cells including cancer cell lines and human primary
hepatocytes. The reported functional mechanism of
RO8191 is selective binding to the I-IFN receptor and the
sequential induction of many interferon-stimulated
genes, followed by the activation of I-IFN signalling
Figure 2 Type I IFNs inhibit prion propagation in infectious cells and animal models. (A) PrPSc levels in N2a-22 L cells 48 h after
treatments with recombinant I-IFNs (rIFNs) (0.1–10 kU/ml). (B–D) Resistance to ex vivo 22 L-prion infection in N2a-58 cells pretreated with rIFNs
(0.1–10 kU/ml) (B), constitutively overexpressing IFN-b (C), or transfected with poly I:C (0.2–2mg) (D). All graphs show quantifications of PrPSc
band intensities. (E and F) Bioassay using 22 L-prion-infected mice (Tga20) inducing Ifnb with lentivirus system. Panels show localization of lentivirus
in thalamus 20 days after stereotaxic injection to Tga20 mice brain (Venus: green; nuclei: blue) (E). Scale bar = 50mm. PrPSc levels in brain of 22 L-
prion-infected mice in the terminal stage brain pre-injected stereotaxically (s.t.) and intracerebrally (i.c.) with LV-venus and -IFN (F). Graphs show
quantifications of PrPSc band intensities in brain (n = 3 mice per each lentiviral injection group). Statistical significance was determined using unpaired
Student’s t-test (C and F) and one-way ANOVA, followed by Dunnett’s test in multiple comparisons (A, B and D). *P5 0.05, **P5 0.01 and
***P5 0.001. Data are presented as mean  SEM. Western blot results represent at least three independent experiments.
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(Konishi et al., 2012). To determine whether IFN-dependent
signalling mediated I-IFN receptor-regulated prion infection,
we investigated PrPSc levels in persistently prion-infected
cells after RO8191 treatment for 48 h. PrPSc levels in
N2a-22 L cells treated with RO8191 were significantly
reduced in a dose-dependent manner (0.5, 5, 50, 250 and
500mM RO8191) (Fig. 5A). However, PrPC levels in N2a-
58 cells treated with RO8191 showed no change (Fig. 5B).
In both cells, the level of 20-50 oligoadenylate synthetase 1a
(OAS1a), encoded by an interferon-stimulated gene, was
dose-dependently increased by RO8191 treatment.
Moreover, we investigated the potential anti-prion effect
of RO8191 in cell culture models. RO8191 pretreated
cells became resistant to 22 L-prion primary infection
with the increase in expression of OAS1a in a dose-depend-
ent manner (Fig. 5C), suggesting that RO8191, which in-
duces interferon-stimulated genes via I-IFN signalling
during the innate immune response, might prevent the es-
tablishment of prion infection without affecting PrPC ex-
pression. Next, to evaluate the efficacy of RO8191
against prion propagation in a prion infectious animal
model, we performed a bioassay using prion-infected
mice. The ddY mice intracerebrally inoculated with 10%
22 L prion brain homogenate were intraperitoneally admin-
istered 2 mg/kg/day RO8191 three times a week from 2
days post-inoculation until sacrifice. The survival periods
of RO8191-treated mice were significantly longer
(165  7 days, n = 8; P = 0.0123, Log-rank test) than
those of the vehicle mice (156  4 days, n = 7) (Fig. 6A).
Changes in the body weight of each group were consistent
with prolonged survival times. The changes in body weight
of the RO8191 group gently decreased compared with
those of vehicle group, and this was delayed by about 2
weeks. RO8191-treated mice were observed for toxicity
due to chronic administration and the symptoms of prion
disease were similar to those of the vehicle mice
(Supplementary Fig. 4A). We analysed PrPSc and histolo-
gical changes in the brains of mice at 100 dpi, which was
the time point before disease onset. PrPSc levels in the
RO8191-treated brains and spleens were significantly less
(50% reduction) than in the vehicle-treated brains at
100 dpi. PrPSc suppression in the spleens of RO8191-trea-
ted mice was observed until the terminal stage (Fig. 6B).
RO8191 treatment significantly inhibited the levels of vacu-
olation and PrPSc deposition in some regions, including the
cortex and spleen, compared with vehicle treatment at
100 dpi. Likewise, we also evaluated gliosis levels in the
brains of RO8191-treated mice at 100 dpi. At 100 dpi,
RO8191 treatment significantly reduced the expression of
Iba-1 and GFAP, which are markers of activated microglia
and astrocytes, in multiple regions of the cortex, thalamus
and pons. However, RO8191 treatment resulted in no
changes in expression in any of the regions at terminal
phase (Fig. 6C, D and Supplementary Fig. 4B). These re-
sults indicate that RO8191 might have the potential to
suppress prion formation in several tissues of the body fol-
lowing exogenous prion infection.
Blood–brain barrier permeability of
RO8191 and concentration in brain
and spleen after chronic
administration
To investigate whether RO8191 functions in the brain, we
performed a blood–brain barrier permeability assay using
the BBB KitTM in vitro. The blood–brain barrier permeabil-
ity coefficient (Papp), which indicates the ability of the
compound to translocate from blood vessels to the brain,
was measured using the BBB KitTM (Pervin et al., 2017).
After 60 min, RO8191 exhibited a significantly higher
blood–brain barrier permeability coefficient (43.94  7.29)
than sodium fluorescein (F-Na), the negative control
(2.66  0.78) (Fig. 7A). Moreover, to confirm the levels
of RO8191 in the tissues of the animal model, we mea-
sured the concentration of RO8191 in the brains and
spleens of prion-infected mice with RO8191 treatment at
Figure 3 Ifnar1 gene depletion is susceptible to prion in-
fection in ex vivo models. (A) PrPSc levels in the indicated
immortalized MEFs from wild-type and Ifnar1/ mice after prion
infection with 6  103 to 1.5  101 % 22 L-brain homogenate
(BH). Graphs show quantification of PrPSc levels in wild-type (black)
and Ifnar1/ (white) cells. *P5 0.05 versus wild-type. (B) Efficiency
of prion infection in cells established by transducing the Ifnar1 gene
into immortalized Ifnar1/ MEFs. Immunoblots show PrPSc after
prion infection with 2  102 % 22 L-brain homogenate. Graphs
show quantification of PrPSc levels in Ifnar1/ (white) and Ifnar1-
transduced (black) cells. **P5 0.01 versus Ifnar1/. Data are
presented as mean  SEM. Statistical significance was determined
using one-way ANOVA, followed by Tukey-Kramer test in multiple
comparisons (A) and unpaired Student’s t-test (B).
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100 dpi and the terminal stage. The concentrations of
RO8191 in the brains and spleens of cured mice at
100 dpi were confirmed to be high 8.44  2.1 and
86.46  62.54mg/g of tissue, respectively, and these con-
centrations were maintained at the terminal stage (Fig.
7B). These results suggest that RO8191 might be able to
act specifically on the brain and spleen, the organs mainly
responsible for establishing prion formation.
Discussion
Prion infection suppressed Ifnb gene expression in 22 L-
prion infected cells, and the level of Ifnb expression re-
covered following reduction of PrPSc by treatment with
anti-prion compound and antibody (Fig. 1). This suppres-
sion of Ifnb gene transcription was followed by the low
expression of IRF3 via a reduction of Oct-1 after prion
Figure 4 Ifnar1 gene depletion is susceptible to prion infection in in vivo animal models. (A–D) Evaluation of prion pathogenesis in
IFNAR1/ mice. (A) Survival curves in wild-type ( + / + ) and Ifnar1/ (/) mice following inoculation intracerebrally (i.c.) with a 101 dilution
of 22 L-brain homogenate (P5 0.001, log-rank test). PrPSc levels (B) and histological changes (C) in the brain at 100 dpi and in terminal phase of
prion infection. (C) Panels show vacuolation (HE), microglia (IBA1), and astrocytes (GFAP) in the cortex (Cx), and PrPSc deposits in cortex and
spleen. Scale bars = 50mm. (D) Lesion profiles of vacuolation, microgliosis, astrogliosis, and PrPSc deposits in the same five brain regions: cortex,
hippocampus (Hi), thalamus (Th), cerebellum (Ce), and pons (Po). Details of the lesion severity score for each histological change are described in
the ‘Materials and methods’ section. Circle and triangle symbols indicate wild-type and Ifnar1/ mice, respectively, at 100 dpi (black) and in the
terminal stage (red). *P5 0.05, **P5 0.01 versus wild-type mice at 100 dpi. Error bars represent SEM. Statistical significance was determined
using unpaired Student’s t-test (D). Results represent at least three independent experiments.
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infection (Homma et al., 2014a). Notably, Tlr3, Ddx58/
RIGI, Ifih1/MDA5 and Irf7, which are innate immune
genes of the upstream signalling pathway relating to I-
IFN induction, were suppressed by prion infection
(Supplementary Fig. 1). IRF3 can contribute to the regula-
tion of gene expression not only for Ifnb but also for Ifih1/
MDA5 (Yount et al., 2007). TLR3 (Heinz et al., 2003),
IRF1 (Choi et al., 2009) and IRF7 (Farlik et al., 2012)
are evoked by STAT1 and NFB is activated by intracellu-
lar signalling in response to IFN-b stimuli. Moreover, IRF1
is a transcription factor that positively regulates RIGI ex-
pression in human cells (Su et al., 2007). These studies
indicate that prion infection might result in a dysfunctional
immune system following the suppression of the expression
of several genes by IRF3 reduction because type I IFN
signalling mediated by IRF3 is closely connected with the
regulation of expression of several innate immunity-related
genes. However, the mechanism of action has not yet been
determined and needs to be investigated in the future.
Although we found that IFN expression remained un-
changed in the brains of prion-infected mice during the
terminal period, it has been reported that the expression
of many interferon-stimulated genes was increased in the
brains of prion-infected animals (Riemer et al., 2000; Xiang
et al., 2004; Stobart et al., 2007). Similarly, the expression
of several interferon-stimulated genes was remarkably
increased in the glial cells of the brains of patients with
Creutzfeldt-Jakob disease (Baker et al., 2004). However,
it remains unclear whether IFN gene expression is increased
in ex vivo and in vivo prion-infected models at an early
phase. Furthermore, it has not been determined whether
IFN in the host plays a protective role against prion patho-
gen infection. In our experiments, prion infection sup-
pressed IFN expression in prion-infected cells (Fig. 1) and
low IFN expression levels were recovered by a reduction of
PrPSc (Fig. 1). Furthermore, pretreatment with IFN and IFN
system stimuli inhibited the new establishment of prion in-
fection (Fig. 2), indicating that the host might combat prion
propagation using any defence system available, including
IFN. Thus, it will be necessary to investigate IFN induction
at an early phase in neurons after prion infection. I-IFN
stimulates various cell types, including immune cells such
as lymphocytes, glia, and neurons (Delhaye et al., 2006;
Paul et al., 2007). Intriguingly, I-IFN is constitutively ex-
pressed at low levels even in the absence of pathogens and
contributes to the regulation of tumour propagation and
cell growth (Taniguchi and Takaoka, 2001). Dysfunction
of TLR4 and IRF3 facilitate prion pathogenesis (Spinner
et al., 2008; Ishibashi et al., 2012a), suggesting that this
process might be negatively regulated by signalling path-
ways, including I-IFN, that act downstream of PRRs.
Pretreatment with complete Freund’s adjuvant and
unmethylated CpG DNA to activate TLR signalling
delays clinical onset in mice after prion inoculation (Sethi
et al., 2002; Tal et al., 2003). Furthermore, glial cells pre-
treated with poly I:C are strongly resistant to prion infec-
tion (Kang et al., 2016), but post-treatment does not
protect against prion pathogenesis in mice (Worthington,
1972; Cunningham et al., 2005; Field et al., 2010). Here,
we showed that I-IFN signalling mediated by IFNAR1 sup-
pressed prion pathogenesis in cell culture and mouse
models after prion inoculation. Although persistent infec-
tion by 22 L prion decreased expression of innate immunity
genes such as Irf3 and Ifnb in an ex vivo system (Homma
et al., 2014a), I-IFN protected against primary prion infec-
tion in cells (Fig. 2). These findings suggest that I-IFN,
induced by TLR signalling, exerts a crucial anti-prion
effect in the early phase after prion infection. Tumor ne-
crosis factor- and interleukin-6, which are induced follow-
ing stimulation of PRR such as TLR4, may contribute to
the acceleration of prion infection as determined by a prion
bioassay using gene-deficient mice (Thackray et al., 2004;
Tamguney et al., 2008). However, the relationship between
suppression and I-IFN signalling has yet to be determined.
Using quantitative high-throughput screening, RO8191
was identified as a novel small molecule that acts like I-
IFNs by directly interacting with the I-IFN receptor to drive
interferon-stimulated gene expression. RO8191 can posi-
tively bind to the IFNAR2 receptor and strongly evoke
an IFN signal inducing interferon-stimulated gene expres-
sion (Konishi et al., 2012). Thus, RO8191 can markedly
block hepatitis C virus replication and cell death after ence-
phalomyocarditis virus infection in cell culture as demon-
strated with recombinant IFN treatment (Konishi et al.,
2012; Wang et al., 2015). Moreover, mice orally inoculated
with RO8191 showed significantly higher expression of
Table 1 Survival periods of prion-infected wild-type and gene-disrupted mice
Gene depletion Infection route Dosec Survival periods (days)a
Wild-type (n)b Ifnar1/(n)b
Ifnar1 Intracerebral 101 153  8 (17) 145  5 (15)**
102 174  4 (10) 162  4 (14)***
Intraperitoneal 102 253  20 (7) 227  5 (6)*
103 273  26 (13) 241  22 (13)***
aSurvival periods are shown as average  SD (days).
b(n), number of mice.
cAnimals were intracerebrally or intraperitoneally administrated with 101 to 103 dilution of brain homogenate from 22 L prion-infected terminal mice. *P5 0.05, **P5 0.01,
***P5 0.001.
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several interferon-stimulated genes compared with the ve-
hicle group (Konishi et al., 2012). RO8191 inhibited PrPSc
in prion-infected cells but did not change the PrPC level
(Fig. 5). Prion-infected mice that were intraperitoneally
treated with RO8191 showed significantly prolonged sur-
vival periods and were resistant to pathological changes in
the brain after prion infection (Fig. 6). Several low molecu-
lar weight compounds (NPRs), which provide stabilization
Figure 5 RO8191 selectively stimulating type I IFN receptor blocks prion formation. (A and B) Effect of RO8191 was investigated in
cell culture models. N2a-22 L (A) and N2a-58 (B) cells were treated with different concentrations (0, 0.5, 5, 250 and 500 mM) of RO8191 for 48 h.
PrPSc (in N2a-22 L), PrPC (in N2a-58), OAS1a and b-actin (as a loading control) were detected by immunoblotting. PrPSc and PrPC band intensities
following treatment with individual RO8191 concentrations are shown as a percentage of the negative control (bottom). (C) Resistance to ex vivo
prion infection in N2a-58 cells pretreated with different concentrations (0, 0.5, 5, 250 and 500 mM) of RO8191. PrPSc, OAS1a and b-actin (as a
loading control) were detected by immunoblotting. Statistical significance was determined using one-way ANOVA, followed by Dunnett’s test in
multiple comparisons. **P5 0.01 and ***P5 0.001. Results in the graph present the mean  SEM from at least three to five independent
experiments.
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of protein structure by binding to PrPC and inhibit conver-
sion to PrPSc, suppressed the prion pathology in prion-in-
fected mice following intraperitoneal chronic treatment.
Several NPRs were linked with significantly reduced PrPSc
levels only in persistently prion-infected cells, with no effect
on PrPC levels (Ishibashi et al., 2016). This implies that
NPRs may show medical efficacy in peripheral areas such
as the spleen, resulting in delayed PrPSc synthesis and ac-
cumulation in the brain. However, it remains to be clarified
whether NPR acts in the brain. In our experiments,
RO8191 was detected in high concentration in the brain
and spleen of prion-infected mice at 100 dpi and at terminal
Figure 6 RO8191-treated mice have resistance against prion infection. (A–D) Evaluation of prion pathogenesis in RO8191-treated
mice. (A) Survival curves for the vehicle and RO8191-treated mice after inoculation intracerebrally (i.c.) with a 101 dilution of 22 L-brain
homogenate (P5 0.05, log-rank test). PrPSc levels (B) and histological changes (C) in the brain (cortex, Cx) and spleen are shown at 100 dpi and
in the terminal phase of prion infection. (D) Lesion profiles in the same five brain regions are similar to those shown in Fig. 4. Circle and triangle
symbols indicate vehicle and RO8191-treated mice, respectively, at 100 dpi (black) and in the terminal stage (red). *P5 0.05 and **P5 0.01 versus
vehicle mice at 100 dpi. Error bars represent SEM. Statistical significance was determined using an unpaired Student’s t-test (B and D). These
results represent at least three independent experiments.
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phase. RO8191 showed high blood–brain barrier perme-
ability in an in vitro system compared with the control
(Fig. 7), indicating that RO8191 might block prion propa-
gation by acting in not only peripheral tissues but also in
the brain. Furthermore, RO8191-treated mice did not have
a shortened life span or show changes in phenotype, such
as rapid weight loss from the side effects, after continuous
treatment (Fig. 6 and Supplementary Fig. 4A), suggesting
that the compound may be safe for clinical application.
In conclusion, the I-IFN pathway contributes to host de-
fence mechanism against prion infection. Although we do
not yet know exactly how host cells can recognize the prion
pathogen, which lacks its own genetic material, the IFR3–
IFN pathway serves as an important line of defence.
Interference with this pathway permits persistent prion in-
fection. The reciprocal interaction between innate host im-
munity and invading prions may explain the long latency of
prion diseases. I-IFN and TLR signalling have diverse func-
tions, including activation of autophagic systems that pro-
mote degradation of -synuclein-derived aggregations
(Ejlerskov et al., 2015; Kim et al., 2015) and contribute
to neuronal homeostasis (Taniguchi and Takaoka, 2001).
Therefore, effects of I-IFN should be considered in further
investigations. Elucidating the role of host immunity in
prion diseases could facilitate development of novel thera-
peutics for this deadly disease.
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